Claims

1. Use of a dopamine agonist and an alpha-2-adrenergic agonist in the manufacture of a medicament for the treatment of hot flashes, wherein the dopamine agonist is capable of binding to one or more of D_2, D_3, or D_4 dopamine receptors or is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor, wherein:
(a) the dopamine agonist that is capable of binding to one or more of the D_2, D_3, or D_4 receptors is Ropinirole, and the alpha-2-adrenergic agonist is Clonidine,
(b) the dopamine agonist that is capable of binding to one or more of the D_2, D_3, or D_4 receptors is Pramipexole, and the alpha-2-adrenergic agonist is Tizanidine,
(c) the dopamine agonist that is capable of binding to one or more of the D_2, D_3, or D_4 receptors is Pramipexole, and the alpha-2-adrenergic agonist is Clonidine,
(d) the dopamine agonist that is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor is Venlafaxine, and the alpha-2-adrenergic agonist is Tizanidine,
(e) the dopamine agonist that is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor is Paroxetine, and the alpha-2-adrenergic agonist is Tizanidine,
(f) the dopamine agonist that is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor is Gabapentin and the alpha-2-adrenergic agonist is Tizanidine,
(g) the dopamine agonist that is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor is Pregabilin, and the alpha-2-adrenergic agonist is Tizanidine, or
(h) the dopamine agonist that is capable of binding to one or more of the D_2, D_3, or D_4 receptors is Rotigotine or Piribidel, and the alpha-2-adrenergic agonist is Tizanidine or Clonidine.

2. The use as set forth in claim 1, wherein the medicament is in a form for administration selected from the group consisting of a pill, an oral liquid form, an intravenous liquid form, a transdermal patch, and an inhalable composition.

3. A composition suitable for treatment of hot flashes, comprising a dopamine agonist and an alpha-2-adreneric agonist, wherein the dopamine agonist is capable of binding to one or more of D_2, D_3, or D_4 dopamine receptors or binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor, wherein:
(a) the dopamine agonist that is capable of binding to one or more of the D_2, D_3, or D_4 dopamine receptors is Ropinirole and the alpha-2-adreneric agonist is Clonidine,
(b) the dopamine agonist that is capable of binding to one or more of the D_2, D_3, or D_4 dopamine receptors is Pramipexole and the alpha-2-adreneric agonist is Tizanidine,
(c) the dopamine agonist that is capable of binding to one or more of the D_2, D_3, or D_4 dopamine receptors is Pramipexole and the alpha-2-adreneric agonist is Clonidine,

(d) the dopamine agonist that is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor is Venlafaxine and the alpha-2-adreneric agonist is Tizanidine,
(e) the dopamine agonist that is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor is Paroxetine and the alpha-2-adreneric agonist is Tizanidine,
(f) the dopamine agonist that is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor is Gabapentin and the alpha-2-adreneric agonist is Tizanidine,
(g) the dopamine agonist that is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor is Pregabilin and the alpha-2-adreneric agonist is Tizanidine, or
(h) the dopamine agonist that is capable of binding to one or more of the D_2, D_3, or D_4 receptors is Rotigotine or Piribidel, and the alpha-2-adrenergic agonist is Tizanidine or Clonidine.

4. A composition as set forth in claim 3 comprising a form which is capable of administration to an individual as a pill.

5. A composition as set forth in claim 4 comprising a form which is capable of administration to an individual as a pill and wherein the dopamine agonist and the alpha-2-adrenergic agonist are separately placed within the pill.

6. A composition as set forth in claim 4 comprising a form which is capable of administration to an individual as a pill and wherein the dopamine agonist and the alpha-2-adrenergic agonist are combined within the pill.

7. A composition as set forth in claim 3 comprising a form which is capable of administration to an individual orally as a liquid.

8. A composition as set forth in claim 3 comprising a form which is capable of administration to an individual intravenously as a liquid.

9. A composition as set forth in claim 3 comprising a form which is capable of administration to an individual by inhalation.